Associated Papers
The role of protective genetic variants in modulating epigenetic aging.
Bejaoui Y et al.
Geroscience, 2025
Drug development advances in human genetics-based targets.
Zhang X et al.
Medcomm, 2024
Angiopoietin-like 3: An important protein in regulating lipoprotein levels.
Burks KH et al.
Best Practice & Research. Clinical Endocrinology & Metabolism, 2023
Genetics of Familial Combined Hyperlipidemia (FCHL) Disorder: An Update.
Taghizadeh E et al.
Biochemical Genetics, 2022
Genetics and regulation of HDL metabolism.
Kardassis D et al.
Biochimica Et Biophysica Acta. Molecular and Cell Biology of Lipids, 2022
Targeting angiopoietin-like 3 in atherosclerosis: From bench to bedside.
Ling P et al.
Diabetes, Obesity & Metabolism, 2021
Low cholesterol syndrome and drug development.
Handhle A et al.
Current Opinion in Cardiology, 2020
Hypobetalipoproteinemia and abetalipoproteinemia: liver disease and cardiovascular disease.
Welty FK
Current Opinion in Lipidology, 2020
Angiopoietin-Like 3: From Discovery to Therapeutic Gene Editing.
Wang X et al.
Jacc. Basic to Translational Science, 2019
Angiopoietin-like protein 3 (ANGPTL3) deficiency and familial combined hypolipidemia.
Tarugi P et al.
Journal of Biomedical Research, 2019
Metabolomic Signature of Angiopoietin-Like Protein 3 Deficiency in Fasting and Postprandial State.
Tikkanen E et al.
Arteriosclerosis, Thrombosis, and Vascular Biology, 2019
New insights into ANGPLT3 in controlling lipoprotein metabolism and risk of cardiovascular diseases.
Su X et al.
Lipids in Health and Disease, 2018
Angiopoietin-like 3 in lipoprotein metabolism.
Kersten S
Nature Reviews. Endocrinology, 2017
ANGPLT3: A novel modulator of lipid metabolism.
Hassan M
Global Cardiology Science & Practice, 2017
Association between familial hypobetalipoproteinemia and the risk of diabetes. Is this the other side of the cholesterol-diabetes connection? A systematic review of literature.
Noto D et al.
Acta Diabetologica, 2017
The role of ANGPTL3 in controlling lipoprotein metabolism.
Tikka A et al.
Endocrine, 2016
What can we learn about lipoprotein metabolism and coronary heart disease from studying rare variants?
Jeff JM et al.
Current Opinion in Lipidology, 2016
Novel therapies for severe dyslipidemia originating from human genetics.
Gaudet D
Current Opinion in Lipidology, 2016
Update on the molecular biology of dyslipidemias.
Ramasamy I
Clinica Chimica Acta; International Journal of Clinical Chemistry, 2016
Insights from exome sequencing for endocrine disorders.
de Bruin C et al.
Nature Reviews. Endocrinology, 2015
Exome sequencing: new insights into lipoprotein disorders.
Farhan SM et al.
Current Cardiology Reports, 2014
Hypobetalipoproteinemia and abetalipoproteinemia.
Welty FK
Current Opinion in Lipidology, 2014
Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis.
Minicocci I et al.
Journal of Lipid Research, 2013
The angiopoietin-like protein 3: a hepatokine with expanding role in metabolism.
Arca M et al.
Current Opinion in Lipidology, 2013
Recent developments in the genetics of LDL deficiency.
Hooper AJ et al.
Current Opinion in Lipidology, 2013
Mutations in the ANGPTL3 gene and familial combined hypolipidemia: a clinical and biochemical characterization.
Minicocci I et al.
The Journal of Clinical Endocrinology and Metabolism, 2012
Allelic and phenotypic spectrum of plasma triglycerides.
Johansen CT et al.
Biochimica Et Biophysica Acta, 2012
Identification of a novel mutation in the ANGPTL3 gene in two families diagnosed of familial hypobetalipoproteinemia without APOB mutation.
Martín-Campos JM et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry, 2012
Prevalence of ANGPTL3 and APOB gene mutations in subjects with combined hypolipidemia.
Noto D et al.
Arteriosclerosis, Thrombosis, and Vascular Biology, 2012
Characterization of three kindreds with familial combined hypolipidemia caused by loss-of-function mutations of ANGPTL3.
Pisciotta L et al.
Circulation. Cardiovascular Genetics, 2012
Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia.
Musunuru K et al.
The New England Journal of Medicine, 2010